

































































Stroke and splenic infarct
in a 17-year-old patient with
COVID-associated hypercoagulable
state and relative ADAMTS13
deficiency
Maximilian Pistor1 , Angelika Hoffmann2, Thomas Horvath1,
Michael Oberholzer1, Marcel Arnold1,
and Sara Magdalena Pilgram-Pastor2
Abstract
In this case report, we present the case of a 17-year-old stroke patient suffering from coronavirus disease (COVID)-19.
He was successfully treated with intravenous and endovascular treatment. After extensive work-up, a hypercoagulable
state due to the COVID-19 infection was assumed as probable cause of stroke.
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We report the case of an otherwise healthy 17-year-old
male patient with acute wake-up stroke. A severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2) infec-
tion was diagnosed 1 week before, presenting as a febrile
disease without clinical respiratory involvement. On
awakening, he experienced unilateral weakness and speech
difficulties. He presented himself febrile and with a
right-sided faciobrachial hemiparesis, a nonfluent aphasia,
possible apraxia of speech, and altered mental status in the
Emergency Room (10/42 on the NIHSS (National Insti-
tutes of Health Stroke Scale).
Initial lab analysis showed an inflammatory profile with
elevations in acute phase reactants and marked leukocyto-
sis. We additionally saw a significantly elevated troponin
(182 ng/ml, n < 14) and B-type natriuretic peptide (BNP;
6847 pg/ml, n < 115).
Magnetic resonance imaging (MRI) of the head revealed
an acute, Fluid-attenuated inversion recovery (FLAIR)-
demarcated stroke in the left middle cerebral artery
(MCA)-territory with an occlusion of the MCA in the distal
M2/M3-junction (Figure 1(a) and (b)B). In addition, a cyto-
toxic lesion of the corpus callosum (CLOCC) was identi-
fied incidentally (Figure 1(d)).
We conducted an intravenous (i.v.) thrombolysis with
alteplase (Actilyse ©; Boehringer-Ingelheim, Germany).
Subsequently, endovascular therapy was performed using
a stent retriever (catch mini©; BALT-Germany) and prox-
imal aspiration through a balloon guiding catheter leading
to successful recanalization (thrombolysis in cerebral
infarction III; Figure 1(b)).
The same day, the patient experienced an acute onset of
left-sided abdominal pain. A computed tomography (CT)-
abdomen showed a partial splenic ischemia, supposedly
due to ongoing embolization. He eventually was fully
anticoagulated (first with unfractionated heparin), later
switched to low-molecular-weight heparin (enoxaparin).
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A CT chest showed no pulmonary signs of coronavirus
disease (COVID)-19 and no sign of pulmonary embolism.
The electrocardiogram (ECG) at admission showed non-
specific ST- and T-changes, a transthoracic echocardiogra-
phy showed no wall motion abnormalities and a normal
systolic/diastolic heart function as well as no valve
abnormalities. With elevations in cardiac biomarkers (tro-
ponin and BNP), ECGs changes, and in light of the known
cardiotropism of SARS-CoV2, we suspected a subclinical
myocardial involvement.
A transesophageal echocardiography showed no intra-
cardiac thrombus or valve vegetations. There were no signs
of patent foramen ovale or arteriovenous fistula on “bubble
testing.” Overall, a paradox-embolic etiology seemed to be
unlikely. Blood cultures drawn at admission returned
without microbial growth, so even in the context of a strong
paraclinical inflammation and fever, endocarditis seemed
to be unlikely. Heart-rhythm monitoring (4 days) showed
no signs of atrial fibrillation as does the ambulatory Holter-
ECG (3  7 days). Taken together, we concluded that there
were no signs of a cardioembolic etiology of the stroke.
Because of the ongoing embolization (brain and spleen),
we decided to not pursue a cerebrospinal fluid analysis
(e.g. for a SARS-CoV2 viral load) and therefore pausing
the anticoagulation. The absence of radiographic signs of
vasculitis in the conventional angiography interventionally,
the CLOCC as a sign of a more systemic inflammation
process, because of the rapid clinical recovery and the
absence of new or suspicious lesions on follow-up imaging
additionally argued against an urgent lumbar puncture.
A hemostaseologic evaluation showed relevant eleva-
tions of D-dimer (2465 mg/L, n < 500) and fibrinogen
Figure 1. Cerebral imaging findings. (a) Tmax and CBV map with FLAIR image and corresponding ADC map illustrating the partial MCA
infarction. (b) The occlusion of the left M2/3 junction branch is shown (square and arrow) on the top row. On the bottom row, the
successfully recanalized vessel can be appreciated (blue arrow) next to the image with expanded stent retriever. (c) After successful
recanalization, subtotal reversal of the ADC lesion was visible. (d) In the initial MRI, a cytotoxic lesion in the splenium of the corpus
callosum was additionally present (shown on diffusion-weighted imaging and the corresponding ADC map, left part), which had resolved
after 4 days (right part). Additionally, a small, most likely peri-interventional ischemic lesion is visible in the caudate nucleus on the left
side on follow-up imaging after 4 days. CBV: cerebral blood volume; FLAIR: fluid-attenuated inversion recovery; ADC: apparent
diffusion coefficient; MCA: middle cerebral artery; MRI: magnetic resonance imaging.
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(5.26 g/L, n < 3.75). Antiphospholipid antibodies were
negative.
We saw elevations of von Willebrand factor (vWF)—
antigen (257%, n (normal range): 42–136%) and activity
(236%, n: 42–168%) on day 4 after stroke and splenic
infarctions. “A disintegrin and metalloproteinase with
thrombospondin 13” (ADAMTS13) activity on day 4
was 93% (n > 51%). The vWF-antigen/ADAMTS13
ratio was 2.7. Factor VIII was also markedly elevated
212% (n: 55–164%).
The patient recovered rapidly and was afebrile on day 3.
The follow-up imaging with MRI showed a timely evolu-
tion of the stroke with a small petechial hemorrhage. The
CLOCC sign was resolving and was barely visible on the
MRI on day 4 (Figure 1(d)). He rapidly left the readaptation
clinic and an extensive neuropsychological work-up
3 months after the event revealed no neuropsychological
as well as subjective sequelae of the stroke. Enoxaparin
was stopped after 4 weeks when hemostaseologic para-
meters normalized. It was switched to aspirin, although the
evidence for secondary prophylaxis in this particular case is
not completely clear.
Discussion
We here presented a case of a young, otherwise healthy,
17-year old with multiple thromboembolic events includ-
ing a “wake up” MCA-occlusion and splenic infarction,
who was tested positive for SARS-CoV2 the week before.
He suffered from a febrile illness without clinical or radio-
graphic signs of pulmonary involvement. A subclinical
myocardial involvement was additionally suspected (tropo-
nin, BNP-elevations, and nonspecific ECG changes). The
stroke was successfully treated with i.v. thrombolysis ther-
apy and mechanical recanalization. After extensive work-
up, no cardio- or paradox-embolic causes of stroke were
identified. We eventually suspected a hypercoagulable
state associated with COVID-19.
Thromboembolic events, especially pulmonary
embolism, occur frequently in SARS-CoV2 infections
and are a significant cause of morbidity and mortality
in COVID-19.1
Stroke also occurs in COVID-19, especially in older
patients with severe disease course and traditional cardio-
vascular disease risk factors and is as high as 5% in some
case series.2 On the other hand, Yaghi et al. also reported a
case series of five young patients suffering from SARS-
CoV2 without respiratory symptoms and stroke.3 A sys-
tematic review of Fridman et al. on COVID-19 and stroke
cases showed for the younger cohort (<50 years) a high
proportion of absent traditional risk factors and comorbid-
ities and higher elevations in troponin and D-dimer.4
The latter may represent a sign of hypercoagulability,
for which the pathophysiology is not completely under-
stood. SARS-CoV2 is able to infect endothelial cells and
cause endotheliitis.5 As one of several mechanisms, some
authors proposed a presumably inflammation-driven
endothelial secretion of vWF and reduced cleavage of large
vWF-polymers by ADAMT13 with enhanced thrombo-
genic potential.6,7
Also in our patient, we detected elevations of vWF-Ag
and factor VIII alongside D-dimer and fibrinogen. The
ADAMTS13-activity was normal with a consecutively ele-
vated vWF-Ag/ADAMTS13 ratio (2.7). Elevation of this
ratio as a substrate of relative ADAMTS13 deficiency in
comparison to vWF as well as factor VIII activation is a
possible substrate of COVID hypercoagulability. A recent
Italian study showed ratios as high as 8 in severely affected
COVID patients on intensive care unit.8 Ratios above 2.6 in
non-COVID stroke patients have been associated with
higher mortality in stroke and decrease by thrombolysis
therapy.9 Therefore, hypothetically, the ratio might be even
higher prior to the thrombolysis in our patient.
Concluding remarks
– Thromboembolic events occur frequently in SARS-
CoV2, also in young patients without traditional car-
diovascular risk factors and without pulmonary or
life-threatening systemic involvement.
– CLOCC occurs in the context of COVID and might
be due to cytokine storm.10 It rapidly disappeared in
follow-up imaging after resolution of systemic
inflammation and fever in our patient.
– Patients with SARS-CoV2-associated hypercoagul-
ability and stroke can effectively be treated by reca-
nalization techniques like i.v. thrombolysis and
mechanical thrombectomy.
– vWF and ADAMTS13 with elevated vWF/
ADAMTS13 ratios in the context of presumed
endothelial damage and endotheliitis might play
a role in COVID hypercoagulability.
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